ERYTECH announces enrollment of first patient in Phase I/II study of eryaspase in Acute Lymphoblastic Leukemia in the United States Post author:admERY Post published:July 22, 2014 Post category:Newsroom ERYTECH announces the enrollment of the first patient in its Phase I/II study with eryaspase in Acute Lymphoblastic Leukemia in the United States of America. You Might Also Like ERYTECH and PHERECYDES announce merger and name change to PHAXIAM Therapeutics June 26, 2023 ERYTECH Hosting Key Opinion Leader Webinar on Eryaspase in Pancreatic Cancer August 24, 2021 ERYTECH announces positive DSMB annual review of its Expanded Access Program in ALL May 5, 2015